The Pulse
Most patients who quit a GLP-1 come back, and sooner than you’d think.
New cohort research reported in mid-June found that 41.5% of patients who discontinue a GLP-1 restart within a year, and 58% restart within two.
That reframes churn. A cancellation in this category is rarely a permanent exit, it’s a pause with a high reinitiation rate baked in.
The question is whether they restart with you or with whoever happens to be in front of them when they decide to try again.
The gap in GLP-1 care isn’t access anymore, it’s what happens after the prescription.
New reporting in early July put a name to the problem: telehealth made these drugs easy to start and left the clinical support that keeps patients on them thin.
Access got solved. Continuity of care did not, and that gap is exactly where month-two churn lives.
The brands adding real provider check-ins, not just refill reminders, are the ones patients stay with once the novelty wears off.
Talkiatry put a number on when telehealth patients drop out.
The virtual psychiatry group published a study identifying clear early-session thresholds that predict who will quit care before they actually do.
Dropout is not random, and it’s not invisible. It shows up as a behavioral signal weeks before the cancellation, in any telehealth vertical, not just psychiatry.
If you can see churn coming, you can intervene while the patient is still active. Most brands only react after the cancel button.
LifeMD is taking testosterone self-pay, and the molecule keeps moving to cash.
LifeMD launched an exclusive self-pay program this month for XYOSTED, a once-weekly testosterone injection, at a transparent price near $249 a month across 37 states.
Another treatment category is going direct-to-patient cash-pay, where there is no insurer keeping the patient in place.
When the patient owns the full bill and the relationship, retention stops being a billing artifact and becomes something you have to earn every month.
The Deep Dive
Your churned patient list is the highest-intent audience you own, and most telehealth brands mail it the least.
Look at the reinitiation data again. 41.5% of GLP-1 quitters restart within a year.
These are people who already chose your category, already went through intake, already know they need the treatment.
They didn’t decide GLP-1s don’t work. They hit a wall, paused, and most of them will be back on something within twelve months.
The only open question is whose name is on the prescription when they return.
Winback is the flow telehealth skips, and it’s the cheapest revenue in the building.
Acquiring a net-new patient means ad spend, intake friction, and a cold relationship.
A lapsed patient costs you one well-timed email. They’ve already paid the acquisition tax once.
Yet most brands treat a cancellation as a dead end. The flow ends, the tag gets set, and the patient never hears from you again until a generic promo blast six months later.
By then they’ve either restarted elsewhere or forgotten you exist. You paid full price to acquire them once and then handed the reinitiation to a competitor for free.
Time the sequence to the reasons they actually left.
The same research names the two dominant reasons people quit: cost and side effects. Build the winback around those, not around a discount.
For the cost-driven leaver:
The math changed since they left. Oral options and the Medicare bridge that went live July 1 put treatment near $50 for eligible patients.
A plan-switch or lower-cost format is a real reason to come back, not a “we miss you” line.
For the side-effect leaver:
They quit because weeks 2 to 6 were rough, not because they gave up on the goal.
A check-in that leads with titration and symptom management, from a provider, reopens the door the cancellation closed.
Half the time the first churn was a support failure, not a treatment failure. Winback works because you can fix the exact thing that pushed them out.
Don’t wait for the anniversary. Catch them in the reinitiation window.
If most restarts happen inside a year, a single annual “come back” email is mistiming the entire opportunity.
Space the touches. A check-in around day 60, a format-and-cost update around day 90, a provider-led note around month 4 to 6.
You’re trying to be the brand in front of them at the exact moment they decide to restart. That moment is a window, not a date.
Each touch carries a different message, because the patient’s reason for staying away shifts over time. Early on it’s the side effects they remember, later it’s the cost, and by month four it’s whether anyone still sees them as a patient at all.
The takeaway: a churned patient in this category is a future buyer with a known intent and a clock running. Build the flow that meets them when the clock goes off.
Quick Takes
The cancel reason you don’t capture is the winback you can’t run.
A winback sequence is only as good as the data you tagged at the moment of cancellation.
Most CRMs mark that a patient left and lose both the molecule they were on and why they quit. That turns your reactivation into a blast instead of a sequence.
Force a structured reason at cancel time and store the treatment. You can’t route someone back to the right offer if you threw away the two fields that decide it.
Self-pay raises the retention bar in every category, not just weight loss.
The XYOSTED launch at $249 cash-pay is the same pattern playing out in men’s health that GLP-1s went through first.
When there’s no insurer locking the patient in, the switching cost drops to a single click. Outcomes and experience become the only thing holding them.
The brands treating cash-pay as a pricing decision are missing it. It’s a retention design decision.
One Thing to Try
Pull every patient who cancelled a GLP-1 in the last 12 months.
Sort them by stated reason. If most are missing a reason, that’s your first fix, but work with what you have.
Take the cost-driven group and draft one email built on what changed since they left: oral access, lower-cost formats, the Medicare bridge for those eligible.
Queue it to send around day 75 to 90 after their cancellation, not on a generic re-engagement schedule.
You’re not running a promo. You’re catching a known buyer in the window where most of them restart anyway.
If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz
Reply to this with your biggest retention challenge. I read and respond to every single one.